成人中13价肺炎球菌结合疫苗与23价多糖疫苗的免疫原性与安全性比较:系统综述与Meta分析
该系统综述与Meta分析纳入5项随机对照试验共4561名50-95.5岁成人,比较单剂PCV13与PPV23的免疫原性(OPA GMT)和安全性。结果显示PCV13在13个血清型中10个的OPA GMT比值显著高于PPV23,局部和全身反应风险整体无差异,但肺炎球菌未暴露者PCV13局部反应更高。
要点
- PCV13在10/13血清型诱导的OPA GMT显著优于PPV23。
- PCV13与PPV23局部和全身反应总体风险无差异。
- 肺炎球菌未暴露成人中PCV13局部反应风险轻度升高。
核心结论
- 单剂PCV13在成人中诱导的免疫应答优于PPV23,安全性特征与PPV23相似。
研究设计与样本
- 系统综述与Meta分析,纳入5项评估单剂PCV13与PPV23在成人中免疫原性的随机对照试验,共4561名50-95.5岁受试者,51%为女性。
主要发现
- PCV13组在13个血清型中的10个(1、4、5、6A、6B、9V、18C、19A、19F和23F)的合并OPA GMT比值显著高于PPV23组。
- PCV13与PPV23的局部和全身反应合并风险比无差异。
- 肺炎球菌未暴露者中PCV13组局部反应显著高于PPV23组(RR:1.15,95%CI:1.05-1.26,p=0.0025)。
关键数值与推荐
- 免疫原性主要指标为接种后1个月的OPA GMT应答。
- 肺炎球菌未暴露者PCV13局部反应RR为1.15(95%CI:1.05-1.26,p=0.0025)。
临床怎么用
- 在成人疫苗接种决策中,PCV13可作为优于PPV23的免疫原性选择,安全性总体相当。
- 对肺炎球菌未暴露成人接种PCV13时,应关注局部反应风险并做好告知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite the use of 23-valent pneumococcal polysaccharide vaccine (PPV23) in adults there is substantial morbidity and mortality in the elderly due to pneumococcal infections. Since 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) is in use for infant immunization programs to reduce rates of pneumococcal disease, but is not routinely used in adults. Recent literature suggests PCV13 may be used in adult vaccination programs as well. OBJECTIVE: To determine the immunogenicity and safety of PCV13 compared with the PPV23 in adults. DESIGN: Systematic review and meta-analysis. SETTING: Randomized controlled trials evaluating immunogenicity of a single dose of PCV13 and PPV23 in adults by the opsonophagocytic assay (OPA) geometric mean titer (GMT) response at 1-month post-vaccination were considered for inclusion. RESULTS: Five randomized trials were included with 4561 subjects ranging 50-95.5 years, consisting of 51% females. The pooled OPA GMT ratio (GMTR) in the PCV13 arm was significantly higher for 10 of 13 serotypes (1, 4, 5, 6A, 6B, 9V, 18C, 19A, 19F and 23F) compared with the PPV23 arm. Overall, pooled risk ratios (RR) for local and systemic reactions did not differ between PCV13 and PPV23. Pneumococcal naïve subjects experienced significantly higher local reactions in the PCV13 arm compared with the PPV23 arm (RR: 1.15, 95%CI: 1.05-1.26, p = 0.0025). CONCLUSION: A single dose of PCV13 elicits a better immune response among adults compared with PPV23, while having a similar safety profile to PPV23.
引用
- Vadlamudi NK, Parhar K, Altre Malana KL, et al. Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine compared to 23-valent pneumococcal polysaccharide in immunocompetent adults: A systematic review and meta-analysis. Vaccine. 2019. PMID: 30685252. doi:10.1016/j.vaccine.2019.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。